Key Takeaways
- FY22 revenue doubled, but Q4 standalone softened: Consolidated revenue grew 109% YoY to ~₹1,600 crore, yet Q4 standalone dipped 2-3% QoQ as the company deliberately walked away from low-margin products.
- Margins compressed sharply, recovery promised by Q2: FY22 EBITDA margin fell to ~11.5% against a 14-15% target, squeezed by raw material inflation and the difficulty of passing through price hikes on black-box formulations. Management expects a return to normal margins by Q2 FY23.
- The Q2 FY22 peak was an anomaly, not a base: An exceptional quarter driven by competitor supply failures created a high-water mark that Q4 could not match; YoY comparisons show growth, and management urges investors to use those instead.
- FY23 guidance is explicit and ambitious: ₹2,000 crore revenue and ₹250 crore EBITDA on a consolidated basis, underpinned by full-year subsidiary contributions, raw material stabilization, and at least 15% volume growth.
- What to watch next quarter: Whether the promised margin recovery to 14-15% actually materializes by Q2 FY23, the pace of raw material softening out of China, and any confirmation of higher EO allocation from Reliance in July.
The Q4 Softening: Anomaly vs. Trend
- Standalone revenue dipped deliberately: Q4 standalone revenue was 2-3% below Q3 because the company chose to ease out of products where margins were not competitive, not because demand collapsed. Overall volumes were flat across all three business segments.
- The Q2 peak was competitor-driven, not structural: In Q2 FY22, supply-chain mismatches left competitors unable to supply, so customers who normally bought small quantities came to Rossari. Management calls that quarter exceptional and not a comparable base, and points to Q4 YoY growth as the real trend.
- HPPC grew YoY despite the Q2-to-Q4 drop: Standalone HPPC moved from ₹108 crore in Q4 FY21 to ₹126 crore in Q4 FY22, roughly 18% YoY growth, even as it fell from the Q2 peak.
- AHN followed the same pattern: AHN Q4 FY22 at ₹25 crore vs ₹21 crore in Q4 FY21 showed YoY growth, though it was down from the ₹38 crore Q2 peak.
- Volume growth was the real engine: Standalone volume growth exceeded 40% for FY22, helped by the Dahej plant becoming fully functional and capitalized towards the end of FY21.
- Revenue composition confirms volume leadership: The ~55% annual revenue growth was approximately 70% volume-driven and 30% price-driven.
Sunil Chari: "Q2 was an exceptional quarter and Q2 sales, if you see also for all the divisions and if you compare Q2 sales to Q4 sales of all the divisions, you'll find it much lesser. But if you compare the HPPC Q4 with HPPC Q4 last year, you'll still find growth in HPPC."
The Margin Problem: Black-Box Pricing and Raw Material Inflation
- FY22 EBITDA margin closed at ~11.5%: This is well below the 14-15% target management considers normal, driven by raw material inflation and the structural difficulty of passing through price increases in formulation products.
- Black-box products create a pricing trap: In formulation or white-label products, the ingredients are not disclosed to the customer, making multiple price increases very difficult without revealing the formulation. In ingredient sales where materials are open, passing on raw material increases is easier.
- White-label customers face their own pass-through problem: Customers who buy white-label products from Rossari are themselves unable to pass on price increases to their end customers, particularly in textiles where cotton prices have surged. Rossari is cautious about pushing price increases on these customers because the white-label business is where its technology strength lies.
- The margin recovery plan has three legs: Price increases that started in March, deliberate product rationalization away from low-margin lines, and an expectation that raw material prices will soften. Management is not relying solely on pricing.
- Q4 gross margins improved slightly QoQ: The company pushed some price increases and moderated sales of lower-margin products, showing early traction on the recovery plan.
- Unitop and Tristar margins disclosed, not absolutes: Unitop EBITDA margin was around 15%, Tristar about 12% in Q4, though management declined to give absolute EBITDA numbers for the subsidiaries.
Edward Menezes: "With the formulation background, since the ingredients are a kind of a black box for the customer, it becomes very difficult to go to the customer with multiple price increases. So we've been increasing our prices from the quarter of March this year and it is becoming impossible to pass on price increases to customers without them knowing what are the ingredients inside."
Acquisitions: Integration and Cross-Selling
- Three acquisitions completed and integrated in FY22: Unitop Chemicals, Tristar Intermediates, and Romakk Chemicals all delivered strong and promising growth during the year, assisting overall performance.
- Acquisitions enhanced technical capacities: The deals brought new capabilities in surfactants and silicones, presented cross-selling opportunities, and enabled several innovations during the year.
- Cross-synergy R&D is already producing results: A joint development exercise between Tristar and Unitop R&D teams at Unitop's pilot plant led to next-generation preservative ingredients with major potential in the export market.
- Spin finish products emerged from Rossari-Unitop collaboration: The application team at Rossari worked jointly with Unitop to develop a range of products for the spin finish market, already approved by key global customers, filling the last textile segment Rossari was not present in.
- Silicone oils leverage Romakk's technical expertise: Using Rossari Dahej's production facility and Romakk's know-how, a new range of silicone oils with low volatile cyclic compounds was manufactured with a focus on sustainability credentials.
- SAP implementation to unify the group: A decision has been taken to implement SAP across all organizations (Rossari plus three acquired companies and two smaller companies) for quicker integration, with a target to go live by the end of FY23.
New Product Pipeline: Seeding Future Revenue
- A novel HPPC ingredient combines polymers and surfactants: This product enhances cleaning performance and allows customers to rationalize quantities used in their formulations, bringing down their formulation cost. Some customer approvals have already been received.
- Buzil Rossari launched Dr. Nanoxa brand: This marks a foray into the nanotechnology space; products offer 30-day antimicrobial and antiviral protection based on unique nanotechnology that stays fixed to any surface.
- TSC filled a major product gap: A new range of products based on polyester chemistry was developed and scaled up at the Dahej site, filling a gap in the TSC portfolio for the sizing market in polyester and cotton fabric.
- Green chemistry innovations target sustainability demand: The R&D team introduced green products to reduce high TDS and save energy by designing products that work at lower temperatures. A sustainable dyeing program for blacks using green chemistry has been successful on knit fabric and is generating interest from big brands.
- AHN launched gut-health products: A new range of esters and glycerides was successfully tested to enhance gut health in poultry and reduce the use of antibiotics and artificial growth promoters. The challenge in India is the lack of regulation, so the company will need to create the market.
- Pet care brands launched on bio-surfactants: New brands based on bio-surfactants and green surfactants have received an excellent response from pet parents.
- Revenue impact will take time: New product ideas are already seeded in the marketplace (low-cyclic-content silicones, sustainable dyeing programs, low-temperature washing programs), but the revenue impact takes time to materialize.
Edward Menezes: "The approach here is not about price increase at all, price increase is the easiest way out and is also very easy way to lose your customer or give entry to competitor into the customer."
Exports: A Small Base Growing Fast
- Exports grew 4x YoY on a consolidated basis: From ₹64 crore last year to ₹264 crore this year, with TSC exports contributing well. Standalone export share increased from 9% to 11.5%.
- Management is building export infrastructure: The company has increased manpower on the export side and expects very strong export growth this year and in coming years.
- Management expects 10-15% export growth: This was stated in the context of overall export focus, not specifically TSC.
- Next-generation preservative ingredients target export markets: The joint Tristar-Unitop development has major potential in the export market.
Raw Material Environment: Waiting on China and Reliance
- The industry continues to witness severe pricing and availability issues: Ongoing geopolitical conflict has further affected the supply chain network, and inflationary pressures impacted margin performance during the year.
- Some softening is happening, but uncertainty remains: Major raw materials are showing a softening trend, but given the lockdown in China and the geopolitical situation, management says it is difficult to guess how the situation will pan out. Currently the trend looks towards softening, but they are still taking a calibrated view.
- EO availability is the critical bottleneck: Reliance has still not confirmed supply for June; enhanced availability is expected from July onwards, subject to confirmation. With the Dahej expansion, the company is hopeful of a higher reallocation from July, subject to confirmation from Reliance.
- Raw material normalization expected by end of Q2 FY23: Management expects the material situation to normalize by then, and they may not be required to do further price increases.
- Subsidiary volumes should benefit: Raw material supplies in subsidiaries are expected to improve, and key raw material EO is expected to stabilize from Q2, helping push better capacity utilization.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue | ₹2,000 crore | FY23 |
| Consolidated EBITDA | ₹250 crore | FY23 |
| Volume growth | At least 15% | FY23 |
| EBITDA margin recovery | Return to 14-15% | By Q2 FY23 |
| Raw material normalization | Material situation normalizes, reducing need for further price hikes | By end of Q2 FY23 |
| SAP go-live | Operations live across all group companies | By end of FY23 |
| EO supply improvement | Higher allocation from Reliance expected | From July (subject to confirmation) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated revenue | ₹439 crore, vs ₹218 crore in Q4 FY21 |
| Standalone organic revenue growth | 30% YoY |
| HPPC segment revenue | ₹304 crore, 69% of total revenue |
| TSC segment revenue | ₹110 crore, 25% of total revenue |
| AHN segment revenue | ₹25 crore, 6% of total revenue |
| Consolidated EBITDA | ₹52 crore, vs ₹35 crore in Q4 FY21 |
| EBITDA margin | 12%, vs 16% in Q4 FY21 |
| PAT | ₹24 crore, vs ₹22 crore in Q4 FY21 |
| FY23 consolidated revenue guidance | ₹2,000 crore |
| FY23 consolidated EBITDA guidance | ₹250 crore |
| Unitop Q4 revenue | ₹124 crore, 4% growth QoQ |
| Tristar Q4 revenue | ₹49.5 crore, about 15% growth QoQ |
| Unitop Q4 EBITDA margin | around 15% |
| Tristar Q4 EBITDA margin | about 12% |
| Standalone HPPC Q4 revenue | ₹126 crore, vs ₹108 crore in Q4 FY21 |
| Group net cash position | ₹52 crore |
| Working capital cycle | below 60 days |
| Final dividend per share | ₹0.5 for FY22 |
| Standalone volume growth FY22 | in excess of 40% |
| FY23 volume growth expectation | at least about 15% |
| Target EBITDA margin | 14%-15% |
| SAP implementation cost | ₹3 crore-₹3.5 crore across the group |